Table 2.

Proposed and observed medication changes related to the patient’s prioritised health outcome

Prioritised health outcome (n = 19)^a	Type of proposed change					Total proposed changes	Total observed changes
Prioritised health outcome (n = 19)^a	Stop	Dose increase	Dose decrease	Switch	Unknown	Total proposed changes	Total observed changes
Remaining alive (n = 6)	5 Desloratadine Mebeverine^b Omeprazole Tamsulosin Tiotropium	1 Levothyroxine	4 Domperidone Macrogol (2×) ^cSimvastatin	1 Temazepam to Melatonin	0	11	3 stopped Mebeverine^b Macrogol (2×)^c
Maintaining independence (n= 7)	7 Alendronic acid^b Atorvastatin Hydrochlorothiazide Omeprazole Propranolol^b Simvastatin Tamsulosin	1 Salbutamol	2 Acetylsalicylic acid Allopurinol^c	0	0	10	3 stopped Alendronic acid^b Propranolol^b Allopurinol^c
Reducing pain (n= 1)	1 Citolapram	0	0	0	0	1	0
Reducing other symptoms (n= 5)	8 Alendronic acid^b Atorvastatin Calcium/vitamin D^b Ferrous sulphate^b Gliclazide^bSimvastatin (3×)^b	0	0	2 Morphine to Buprenorphine Acenocoumarol to Acetyl-salicylic acid^c	1 Morphine^c	11	7 stopped Alendronic acid^b Calcium/vitamin D^b Ferrous sulphate^b Gliclazide^b Simvastatin (2×)^b Acenocoumarol^c 1 dose decrease Morphine^c
Total	21^a	2	6	3	1	33^a	14

↵a One patient gave the highest priority to both maintaining independence and reducing other symptoms, and is not included (proposed but not observed stop of betahistine).
↵b Observed change in agreement with the proposed change.
↵c Observed change adapted from the proposed change, or agreement unknown.